SCHEMBL21166

SCHEMBL21166

Cc1ccc(CO)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyanide SCHEMBL28127987 0.94 CCR1 (0.43)
SCHEMBL27483191 0.88 CCR1 (0.39)
SCHEMBL1683332 0.82 CCR1 (0.44)
SCHEMBL18682734 0.80 CCR1 (0.52)
SCHEMBL14573460 0.80 CCR1 (0.52)
SCHEMBL8665678 0.79 CCR1 (0.41)
SCHEMBL469189 0.78
SCHEMBL20099862 0.77 PDE10A (0.42)
SCHEMBL9290490 0.76
SCHEMBL9645202 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0815108-A1 CYCLIC UREA HIV PROTEASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-01-07 EP claimed
US-5683999-A Cyclic urea HIV protease inhibitors THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-11-04 US claimed
WO-1996029329-A1 CYCLIC UREA HIV PROTEASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-09-26 WO claimed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-12570666-B2 Furoindazole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2026-03-10 US disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12552799-B2 Triazolone compounds NXERA PHARMA UK LIMITED (GB) 2026-02-17 US disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer NXERA PHARMA UK LIMITED (GB) 2026-01-20 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
EP-4598916-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 EP disclosed
EP-0313630-B1 SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) 1992-09-16 EP disclosed
US-5084458-A Bactericides, malaria and antitumor agents SCHAPER KLAUS JUERGEN (DE) 1992-01-28 US disclosed
US-4997835-A Bactericides, malaria, antitumor SCHAPER KLAUS JUERGEN (DE) 1991-03-05 US disclosed
EP-0313630-A1 SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. DEUTSCHES AUSSATZIGEN HILFSWER (DE) 1989-05-03 EP disclosed
EP-0163842-A1 Tricyclic imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1985-12-11 EP disclosed
EP-0001279-B1 IMIDAZOLE DERIVATIVES THEIR SYNTHESIS AND THEIR PHARMACEUTICAL FORMULATIONS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-09-30 EP disclosed
US-4248880-A IMIDAZOLE OR THIAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 1981-02-03 US disclosed
US-4182766-A ANTIULCER AGENTS HOFFMANN-LA ROCHE INC. (US) 1980-01-08 US disclosed
EP-0001279-A1 Imidazole derivatives their synthesis and their pharmaceutical formulations F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-04-04 EP disclosed